根据解剖严重程度分级评分评估Endurant II覆膜支架的结局
这项回顾性研究纳入2013年1月至2021年5月接受Endurant II覆膜支架治疗的165例连续患者,按解剖严重程度分级(ASG)评分分为低分(<14分,110例)和高分(>14分,55例)两组,比较早期与中期结局。结果显示两组技术成功率均为100%,30天主要临床成功率为100%,1年为96%;高分组的合并并发症和植入物相关并发症更高,免于再干预率和累积生存率更低,但作者认为Endurant II腔内修复在两组中似乎均安全。
要点
- 165例连续患者中低ASG评分组110例(67%),高ASG评分组55例(33%)。
- 高分组合并并发症29% vs 低分组的8%(p<0.001),植入物相关并发症13% vs 4%(p=0.043)。
- 低分组免于再干预率在1、2、3年分别为97%、96%、96%,高于高分组的90%、88%、85%(p=0.035)。
核心结论
- 作者认为Endurant II腔内修复在低分和高分患者中似乎均安全,但高分组的植入物相关并发症和中期死亡率高于低分组。
研究设计与样本
- 回顾性研究,纳入2013年1月至2021年5月接受Endurant II覆膜支架治疗的165例连续患者(89%为男性,年龄74±8岁)。
- 按ASG评分分为低分(评分<14)组110例(67%)和高分(评分>14)组55例(33%)。
主要发现
- 技术成功率为100%,30天主要临床成功率为100%,1年主要临床成功率为96%。
- 中位手术时间高分组长于低分组(133 vs 120分钟,p=0.116),无统计学意义。
- 低分组中位剂量面积乘积为50.9 Gy·cm2(IQR 22.4-75.5 Gy·cm2),显著低于高分组的85.0 Gy·cm2(IQR 46.5-127.9 Gy·cm2),p=0.025。
- 低分组中位透视时间为17分钟(IQR 13-24分钟),低于高分组的19分钟(IQR 16-23分钟),p=0.148,无显著差异。
- 中位随访32个月(范围2-63个月)时,高分组合并并发症29% vs 低分组8%(p<0.001),植入物相关并发症13% vs 4%(p=0.043)。
关键数值与推荐
- 低分组免于再干预的Kaplan-Meier估计在1、2、3年分别为97%、96%、96%,高于高分组的90%、88%、85%(p=0.035)。
- 低分组累积生存率在1、2、3年分别为99%、98%、96%,高于高分组的87%、85%、82%(p=0.001)。
- 30天全身并发症在高分组为15% vs 低分组11%(p=0.500),无统计学显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study's objective was to evaluate Endurant II (Medtronic Inc, Minneapolis, Minnesota) stent graft's early and midterm outcomes and compare the results according to the anatomic severity grade (ASG) scores. METHODS: This was a retrospective study of patients treated with the Endurant II stent graft between January 2013 and May 2021. The patients were divided into 2 independent groups, including those with a low ASG score (score <14) and a high ASG score (score >14). RESULTS: A total of 165 consecutive patients (89% males, age 74±8 years) were included. There were 110 (67%) patients in the low-score group and 55 (33%) patients in the high-score group. Technical success was achieved in all cases. Primary clinical success at 30 days was 100% and at 1 year was 96%. Median operative time was longer in the high-score group with no statistical significance (133 vs 120 minutes, p=0.116). The median dose area product of low-score patients (50.9 Gy·cm2; IQR 22.4-75.5 Gy·cm2) was significantly lower than high-score patients (85.0 Gy·cm2; IQR 46.5-127.9 Gy·cm2) with p=0.025. Median fluoroscopic time was lower in low-score patients (17 minutes; IQR 13-24 minutes) compared with high-score patients (19 minutes; IQR 16-23 minutes) without a significant difference at p=0.148. At a midterm follow-up of 32 months (range 2-63 months), combined complications (29% vs 8%, p<0.001) and implant-related complications (13% vs 4%, p=0.043) were higher in the high-score group. Systemic complications at 30 days were higher in the high-score group without a statistically significant difference (15% vs 11%, p=0.500). The Kaplan-Meier estimate of freedom from reintervention was significantly higher in the low-risk group at 1 (97% vs 90%), 2 (96% vs 88%), and 3 years (96% vs 85%) with (p=0.035). The cumulative survival rate was significantly higher in the low-score group than high-score group (p=0.001) at 1 (99% vs 87%), 2 (98% vs 85%), and 3 years (96% vs 82%). CONCLUSIONS: Endurant II endovascular aneurysm repair seems to be safe in both low-score and high-score patients. However, patients in the high-score group showed more implant-related complications and midterm mortalities than those in the low-score group.
引用
- Omran S, Müller V, Schawe L, et al. Outcomes of Endurant II Stent Graft According to Anatomic Severity Grade Score. J Endovasc Ther. 2022. PMID: 35466775. doi:10.1177/15266028221090433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。